Akebia Therapeutics Receives UK Approval for Vadadustat to Treat CKD Anemia
May 23, 2023
Trending News ☀️
Akebia Therapeutics ($NASDAQ:AKBA), a biopharmaceutical company focused on kidney disease, has received approval from the UK for its vadadustat drug to treat anemia in patients with chronic kidney disease (CKD). Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, which regulates the production of red blood cells. This approval marks an important milestone in the development of innovative therapies for CKD. Akebia Therapeutics is a company dedicated to the discovery, development and commercialization of novel therapeutics for people with kidney diseases. The company focuses on expanding treatment options for patients with anemia and other complications of CKD. It has a pipeline of small molecule compounds for the treatment of anemia related to CKD and other serious conditions.
The UK approval of vadadustat is an important step in Akebia’s mission to provide effective treatments for people with kidney disease. The company is currently evaluating vadadustat in clinical trials in the US and Japan. They are also exploring potential combination therapies with other therapeutic agents that may further improve the treatment of anemia in CKD patients. With this approval, Akebia is now one step closer to providing a much needed therapy for CKD patients worldwide.
Stock Price
On Monday, AKEBIA THERAPEUTICS received approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to market Vadadustat, its oral hypoxia-inducible factor prolyl hydroxylase inhibitor, as a treatment for anemia associated with chronic kidney disease (CKD). The news sent AKEBIA stocks soaring 21.6% from its closing price of $1.2 the previous day, opening at $1.3 and closing at $1.4. This approval marks a significant milestone for the company as it continues to provide life-saving treatments to patients with CKD anemia. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Akebia Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 271.03 | -56.36 | -14.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Akebia Therapeutics. More…
| Operations | Investing | Financing |
| -69.07 | 0 | -48.91 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Akebia Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 276.86 | 291.21 | -0.08 |
Key Ratios Snapshot
Some of the financial key ratios for Akebia Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -8.2% | – | -11.2% |
| FCF Margin | ROE | ROA |
| -25.5% | 760.5% | -6.9% |
Analysis
At GoodWhale, we conducted an in-depth analysis of AKEBIA THERAPEUTICS, taking into account various financial and business aspects. Based on our Risk Rating, AKEBIA THERAPEUTICS is a high risk investment. In particular, our analysis has detected three risk warnings in the income sheet, balance sheet, and cashflow statement. If you are interested in learning more about these risks, please register on our website at goodwhale.com. We provide detailed information regarding all of our assessments, as well as recommendations for any potential investments. More…
Peers
It engages in research, development, and commercialization of small molecule therapeutics that promote kidney health. Akebia has several competitors in the market, including Nascent Biotech Inc, MEI Pharma Inc, and Albireo Pharma Inc. All these companies are working hard to develop innovative treatments for kidney diseases and other related conditions.
– Nascent Biotech Inc ($OTCPK:NBIO)
Nascent Biotech Inc is a biotechnology company that specializes in the development of novel gene therapies for cancer and other diseases. As of 2023, the company has a market cap of 13.69M and a Return on Equity of 65.07%. The market cap of Nascent Biotech Inc represents the total value of its outstanding shares, which reflects investor confidence in its products and services. The high ROE suggests that the company is making efficient use of its shareholders’ equity to generate profits and reward shareholders with dividends.
– MEI Pharma Inc ($NASDAQ:MEIP)
MEI Pharma Inc is a pharmaceutical company engaged in the development and commercialization of treatments for cancer. The company’s market cap as of 2023 was 30.56M. The Return on Equity (ROE) for the company was -68.64%. This indicates that the company has been experiencing a decrease in its shareholder equity, indicating that it is not generating enough revenue to cover its liabilities. Despite this, MEI Pharma Inc continues to pursue innovative strategies in its attempt to develop treatments for cancer.
Summary
Akebia Therapeutics has recently seen a rise in its stock price after receiving approval from the UK for its anemia treatment, Vadadustat. The approval of the drug is a significant milestone for the company, as it marks the first step towards a successful commercial launch in Europe. Investors are optimistic that this approval will lead to further success for the company and open up new revenue opportunities.
The potential of Vadadustat and other products in Akebia Therapeutics’ pipeline have caused many analysts to recommend purchasing shares of the company. While there is a degree of risk associated with any healthcare stock, the potential reward makes Akebia Therapeutics an attractive investment opportunity.
